A5061619334- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Mesenchymal stem cell research
- Nanoplatforms for cancer theranostics
- Congenital Anomalies and Fetal Surgery
- Occupational and environmental lung diseases
- Muon and positron interactions and applications
- Renal and related cancers
- CAR-T cell therapy research
- Head and Neck Cancer Studies
- Cell Adhesion Molecules Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Medical Imaging Techniques and Applications
- Immunotherapy and Immune Responses
- Radiation Therapy and Dosimetry
- Peptidase Inhibition and Analysis
University of Pittsburgh
2023-2025
UPMC Hillman Cancer Center
2023
Sri Balaji Vidyapeeth University
2017
Abstract Radiopharmaceutical therapy (RPT) is a promising approach to treating solid tumors, but therapeutic advances are impeded by the lack of broadly expressed targets and shared molecular vulnerability across different tumor types. Here, we evaluate VLA-4 (integrin α4β1) as potential target for RPT in tumors use radiolabeled copper-64 ([64Cu]Cu-) copper-67 ([67Cu]Cu-CB-TE1A1P-PEG4-LLP2A) LLP2A, peptidomimetic ligand VLA-4, preclinical imaging testing. Expression ITGA4, gene encoding...
<p>(A) Platelet counts weekly after [67Cu]Cu-LLP2A treatment. (B) Creatinine, (C) alanine aminotransferase (ALT), and (D) total bilirubin collected in animals 5 months treatment with 55.5 MBq (1.5 mCi) of or control (PBS). Unpaired t-test; ns = not significant.</p>
<p>Table of mouse models for each tumor type</p>
<div>Abstract<p>Radiopharmaceutical therapy (RPT) is a promising approach to treating solid tumors, but therapeutic advances are impeded by the lack of broadly expressed targets and shared molecular vulnerability across different tumor types. Here, we evaluate VLA-4 (integrin α4β1) as potential target for RPT in tumors use radiolabeled copper-64 ([<sup>64</sup>Cu]Cu-) copper-67 ([<sup>67</sup>Cu]Cu-CB-TE1A1P-PEG<sub>4</sub>-LLP2A) LLP2A,...
<p>Immunohistochemistry staining of human CD3 spleen and tumor (IMR-5) for detection CAR T-cell engraftment.</p>
<p>(A) Time course biodistribution study with [67Cu]Cu-LLP2A in tumor-bearing mice B16-F10 melanoma. (B) Muscle is used as reference tissue for non-specific uptake. Mixed-effects analysis Dunnett’s multiple comparisons test; ****P < 0.0001; ***P 0.001; **P 0.01; *P 0.05; ns = not significant.</p>
<p>(A) PET/CT imaging and (B) biodistribution study with [64Cu]Cu-LLP2A in osteosarcoma 143B-bearing mice. Muscle is used as reference tissue for non-specific uptake. One-way ANOVA Tukey’s multiple comparisons test; ****P < 0.0001.</p>
<p>Successful radiolabeling of LLP2A with copper-64 ([64Cu]Cu) for further imaging studies. Radiochemical purity [64Cu]Cu-LLP2A was confirmed to be >98% by (A) radio-thin-layer chromatography (radio-TLC) and (B) radio-high-performance liquid (radio-HPLC) analysis.</p>
<p>(A) PET/CT imaging, (B) biodistribution study, and (C) dosimetry analysis with [64Cu]Cu-LLP2A in melanoma B16-F10–bearing male C57BL/6J mice. Muscle is used as reference tissue for non-specific uptake. One-way ANOVA Tukey’s multiple comparisons test; ****P < 0.0001; **P 0.01. (D) Biodistribution study female mice B16-F10 melanoma. Most tissues show no difference between females males exception of the spleen kidney. Two-way Sidak’s ***P 0.001; *P 0.05.</p>
<p>Histologic evaluation of end-organs 30 days after [67Cu]Cu-LLP2A treatment. (A) H&E staining and (B) pathologic findings.</p>
Abstract Background The liver is a common site for metastatic disease variety of cancers, including colorectal cancer. Both primary and secondary tumors are supplied through the hepatic artery while healthy by portal vein. Transarterial radioembolization (TARE) using yttrium-90 glass or resin microspheres have shown promising results with reduced side-effects but similar survival benefits as chemoembolization in patients hepatocellular carcinoma (HCC). This highlights need new novel agents...
Mesothelin (MSLN) is a tumor-associated antigen found in variety of cancers and target for imaging therapeutic applications MSLN-expressing tumors. We have developed high affinity anti-MSLN human VH domain antibodies, providing alternative targeting vectors to conventional IgG antibodies that are associated with long-circulating half-lives poor penetration tumors, limiting antitumor activity clinical trials. Based on two newly identified binders (3C9, 2A10), we generated VH-Fc fusion...
Abstract Purpose: The purpose of this study was to develop a new anti-programmed death-ligand 1 (αPD-L1) interleukin-15 (IL-15) diabody (Db) immunocytokine improve the efficacy combination radiation therapy (RT) and immune checkpoint inhibition (ICI) treatment in head neck cancer. Background ICI has revolutionized cancer care by increasing survival patients with metastatic cancer, yet many poorly immunogenic tumors have limited response therapy. To ICI, we developed combining an αPD-L1 Db...
Background and Objective: Stem cells have been isolated from various parts of the human body including bone marrow, umbilical cord blood adipose tissue. Human breast milk as a source stem is less studied with limited reports. In this pilot work, we investigated cell-like properties derived colostrum using in vitro mechanistic assays.Material Methods: Institutional Committee for Stem Cell Research’s approval written informed consent volunteering mothers were obtained prior to sample...